Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma

Anticancer Research

Volumn 29, Issue 8, 2009, Pages 3281-3288

  Lashkari, Ashkan ^a   Chow, Warren A ^a   Valdes, Frances ^a   Leong, Lucille ^a   Phan, Vu ^a   Twardowski, Przemyslaw ^a   Kapoor, Neena ^a   Molina, Arturo ^a   Al Kadhimi, Zaid ^a   Frankel, Paul ^a   Somlo, George ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Autologous transplantation; Ewing's sarcoma; High dose chemotherapy; Rhabdomyosarcoma

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; MESNA; VINCRISTINE;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTOTRANSPLANTATION; BACTEREMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EWING SARCOMA; FEBRILE NEUTROPENIA; FEMALE; HEART ARRHYTHMIA; HEMATURIA; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; INFECTION; LEUKOPENIA; LUNG DISEASE; LUNG INFILTRATE; MALE; METASTASIS; MOOD DISORDER; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PARTIAL THROMBOPLASTIN TIME; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SEPSIS; SIDE EFFECT; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DOXORUBICIN; FEASIBILITY STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IFOSFAMIDE; IMMUNOENZYME TECHNIQUES; MALE; MELPHALAN; MESNA; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUROECTODERMAL TUMORS, PRIMITIVE, PERIPHERAL; OSTEOSARCOMA; PROGNOSIS; PROSPECTIVE STUDIES; PROTECTIVE AGENTS; REMISSION INDUCTION; RHABDOMYOSARCOMA; SAFETY; SARCOMA; SARCOMA, EWING'S; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 68549104150     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer Statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, Verweij J, Santoro A, Buesa J and Tursz T: Prognostic factors in advanced soft tissue sarcoma: analysis of 2185 patients treated with anthracycline containing first-line regimens - a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol 17: 150-157, 1999. (Pubitemid 29022388)
3. Demetri GD and Elias AD: Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas: Implications for decision making in the clinic. Hematol Oncol Clin N Am 9: 765-785, 1995.
4. Reichardt P, Tilgner J, Hohenberger P, Dorken B: Dose intensive chemotherapy with ifosfamide, epirubicin, and figastrim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol 16: 1438-1443, 1998. (Pubitemid 28175763)
5. Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S and Parkinson DR: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against soft tissue sarcomas. J Clin Oncol 11: 1269-1275, 1993. (Pubitemid 23199129)
6. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E, Kirkpatrick A, Van Glabbeke A and van Oosteram A: Doxorubicin versus CyVADic versus ifosfamide plus doxorubicin in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13: 1537-1545, 1995.
7. Horowitz ME, Kinsella TJ, Wexler LH, Belasco J, Triche T, Tsokos M, Steinberg SM, McClure L, Longo DL, Steis RG,Glatstein E, Pizzo PA and Miser JS: Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol 11: 1911-1918, 1993.
8. Boulad F, Kernan NA, LaQuaglia MP, Heller G, Lindsley KL, Rosenfield NS, Abramson SJ, Gerald WL, Small TN, Gillio AP, Gulati SC, O'Reilly RJ and Ghavimi F: High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma. J Clin Oncol 16: 1697-1706, 1998. (Pubitemid 28234712)
9. Blay JY, Bouhour D, Ray-Coquard I, Dumontet C, Philip T and Biron P: High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. J Clin Oncol 18: 3643-3650, 2000. (Pubitemid 30816222)
10. Wiklund T, Saeter G, Strander H, Alvegård T and Blomqvist C: The outcome of advanced soft tissue sarcoma patients with complete tumor regression after either chemotherapy alone or chemotherapy plus surgery: the Scandanavian Sarcoma Group experience. Eur J Cancer 33: 357-361, 1997. (Pubitemid 27168059)
11. + selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer. Blood 89: 1521-1528, 1997. (Pubitemid 27097443)
12. Ladenstein R, Lasset C, Pinkerton R, Zucker JM, Peters C, Burdach S, Pardo N, Dallorso S and Coze C: Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant 15: 697-705, 1995.
13. Burdach S, Meyer-Bahlburg A, Laws HJ, Haase R, van Kaik B, Metzner B, Wawer A, Finke R, Göbel U, Haerting J, Pape H, Gadner H, Dunst J and Juergens H: High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol 21: 3072-3078, 2003. (Pubitemid 46606287)
14. Frei E, Cucchi Ca, Rosowsky A, Tantravahi R, Bernal S, Ervin TJ, Ruprecht RM and Haseltine WA: Alkylating agent resistance: In vivo studies with human cell lines. Proc Natl Acad Sci USA. 82: 2158-2162, 1986, 1985.
15. Kasper B, Dietrich S, Mechtersheimer G, Ho AD and Egerer G: High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. Oncology 73: 58-64, 2007.
16. Barker LM, Pendergrass TW, Sanders JE and Hawkins DS: Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol 23: 4354-4362, 2005. (Pubitemid 46207009)
17. Blay JY, van Glabbeke M, Verweij J, van Oosterom AT, Le Cesne A, Oosterhuis JW, Judson I and Nielsen OS: Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 39: 64-69, 2003. (Pubitemid 36005426)
18. Yuen JS and Macaulay VM: Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets 12: 589-603, 2008. (Pubitemid 351699478)